Karmactive StaffNorgine Limited has initiated a Class 3 recall of MOVICOL Plain 13.7g powder for oral solution due to a manufacturing issue affecting specific batches of the commonly used laxative medication. The UK Medicines and Healthcare products Regulatory Agency (MHRA) issued the recall on 5 October 2026 as a precautionary measure following the discovery that some units within the affected batches contained incorrect amounts of active ingredients.
What Products Are Affected
The recall applies specifically to MOVICOL Plain 13.7g powder for oral solution, a preparation used to treat constipation. Two batches have been identified as requiring recall:
Batch number 487069, with an expiry date of 28 February 2029 and a pack size of 30 units, was first distributed on 5 June 2026.
Batch number 474919, with an expiry date of 31 August 2028 and a pack size of 30 units, was first distributed on 7 November 2025.
The product contains four active ingredients: macrogol 3350, sodium chloride, sodium hydrogen carbonate, and potassium chloride. The product’s marketing authorization holder is Norgine Limited, with product license number 20142/0004 and GTIN 05012748615328.
Why Was This Recalled
Norgine Limited initiated this recall as a precautionary measure after detecting that some units within the affected batches contained incorrect amounts of active ingredients. The specific nature of the dosage variation has not been publicly detailed, but the MHRA’s classification as a Class 3 recall indicates a serious potential health risk if the defective product were to remain in distribution through normal channels.
What You Should Do
For patients: Those currently in possession of affected batches may continue to take this medicine. No action is required on the patient’s part, as the recall is being managed at retail and wholesaler levels rather than through consumer returns. Patients who experience any adverse reactions or have concerns about their medication should contact their healthcare provider. Any suspected adverse reactions should be reported to the MHRA through the Yellow Card reporting scheme.
For healthcare professionals and pharmacy staff: Stop supplying the identified batches immediately and quarantine all remaining stock. Return all quarantined product to your supplier using their approved return process. NHS regional teams are distributing this notice to community pharmacies and dispensing general practitioners.
For product enquiries: Medical information questions should be directed to Norgine Limited at MedInfo@norgine.com or +44 (0) 1895 826606. Stock control matters should be addressed to UKIsupport@norgine.com or +44 (0) 1895 826600.
Official Recall Details
The official MHRA safety notice sets out the regulator’s reference and instructions.
DMRC Reference Number: DMRC – 40129134
Recall Classification: Class 3 Medicines Recall
Issuing Authority: Medicines and Healthcare products Regulatory Agency (MHRA)
Date Issued: 5 October 2026
Marketing Authorisation Holder: Norgine Limited
The MHRA’s Defective Medicines Report Centre issued this recall and continues to monitor the situation. This coordinated response between the manufacturer and regulatory authorities reinforces the importance of quality control mechanisms within pharmaceutical manufacturing and distribution. Consumers experiencing concerns about any medication should always consult their healthcare provider or contact the appropriate regulatory body for guidance. For related coverage, see Cold Medicine Paracetamol Overdose Warning NHS Liver Failure and Generic Zyrtec (Cetirizine) Recalled Nationwide Over Heartburn Drug Contamination — Check Your Lot Numbers Now.
